Canopy Growth buys German medical cannabis company for $343 million


SMITHS FALLS, Ont. — Canopy Growth Corp. has signed a deal to buy a German company that specializes in cannabinoid-based medical therapies used by European physicians for roughly $342.9 million. Under the deal, the Ontario-based company has acquired C3 Cannabinoid Compound Co. C3’s main medicinal offering is dronabinol, a compound with standardized concentrations of THC (tetrahydrocannabinol), the main psychoactive compound in cannabis. Dronabinol is available in Austria, Denmark and Germany.

Ga naar Bron